LFB S.A. Increases Its Capital by 230 Million Euros

LES ULIS, France–(BUSINESS WIRE)–Regulatory News:

Designed to support the development of the LFB group, this capital
increase was voted by LFB S.A’s Board of Directors on 18th September,
and was approved in General meeting of shareholders on 2
nd
October. It will be wholly subscribed by the French State which is the
unique shareholder of LFB S.A.

The release schedule is based on four successive steps between the first
subscription before 16th October 2015, for 60 million euros,
and the fourth subscription planned for April 2018 latest. At the end of
the operation, the authorized capital of LFB S.A. will be of 280 million
euros (280 000 000 euros), falling into five millions and six hundreds
of thousands (5 600 000) shares of fifty euros (50 euros) each.

This capital increase aims at supporting the development of the LFB
group for the years to come, namely with the financing of a new
manufacturing facility for plasma-derived medicinal products. Located in
the north of France, this “next generation” plant is to start in 2020
and allow LFB to triple within the next ten years, its global production
capacity for plasma-derived medicinal products. It will also upgrade the
production costs in order to strengthen the group’s competitiveness in a
highly technological field, and meet the highest global standards,
allowing LFB to increase its international sales.

About the LFB group. The
LFB group (
www.lfb.fr)
is a biopharmaceutical company that develops, manufactures, and markets
medicinal products for the treatment of serious and often rare diseases
in the fields of Immunology, Hemostasis, Perinatal, and Intensive Care.
The LFB group is the leading manufacturer of plasma-derived medicinal
products in France and 6th worldwide, and is also among the leading
European companies for the development of new-generation medicinal
products or treatments based on biotechnologies.

The LFB
group is pursuing a growth strategy that seeks to extend its
international activities and develop innovative therapies. Today, the
LFB group markets its products in more than 40 countries around the
world with a global turnover of € 501.9 million in 2014.
www.lfb.fr

Contacts

LFB S.A
Sandrine Charrières, Phone: +33 (1) 69 82 72 80
Executive
VP Corporate Communications
email : charrieres@lfb.fr
or
Media
relations contact:

Havas Worldwide
Jeanne Bariller,
Phone : +33 (6) 15 51 49 40
jeanne.bariller@havasww.com